A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

NCT04818229 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

112

Enrollment

INDUSTRY

Sponsor class

Conditions

Autoimmune Diseases

Interventions

DRUG: CBP-307
DRUG: Placebo-matched CBP-307
DRUG: Moxifloxacin (Avelox)
DRUG: Placebo-matched Moxifloxacin

Sponsor

Connect Biopharma Australia Pty Ltd